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Abstract
Background: Rehabilitation of patients with chronic obstructive pulmonary disease (COPD) is a key treatment in COPD.
However, despite the existing evidence and a strong recommendation from lung associations worldwide, 50% of patients
with COPD decline to participate in COPD rehabilitation program and 30–50% drop-out before completion. The main
reasons are severe symptoms, inflexible accessibility and necessity for transportation. Currently there are no well-
established and evident rehabilitation alternatives. Supervised online screen rehabilitation could be a useful approach to
increase accessibility and compliance. The aim of this multicenter RCT study is to compare the potential benefits of a 10-
week online COPD rehabilitation program (CORe) with conventional outpatient COPD rehabilitation (CCRe).
Methods: This study is a randomized assessor- and statistician blinded superiority multicenter trial with two parallel
groups, employing 1:1 allocation to the intervention and the comparison group.On the basis of a sample size calculation,
134 patients with severe or very severe COPD and eligible to conventional hospital based outpatient COPD rehabilitation
will be included and randomized from eight different hospitals. The CORe intervention group receives group supervised
resistance- and endurance training and patient education, 60 min, three times/week for 10 weeks at home via online-
screen. The CCRe comparison group receives group based supervised resistance- and endurance training and patient
education, 90 min, two times/week for 10 weeks (two hospitals) or 12 weeks (six hospitals) in groups at the local hospital.
The primary outcome is change in the 6-min walking distance after 10/12 weeks; the secondary outcomes are changes in
30 s sit-to-stand chair test, physical activity level, symptoms, anxiety and depression symptoms, disease specific and
generic quality of life. Primary endpoint is 10/12 weeks from baseline, while secondary endpoints are 22, 36, 62 weeks
from baseline assessments.
Discussion: The study will likely contribute to knowledge regarding COPD tele-rehabilitation and to which extent it is
more feasible and thereby more efficient than conventional COPD rehabilitation in patients with severe and very
severe COPD.
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Background
Chronic Obstructive Pulmonary Disease (COPD) is a major
cause of chronic morbidity and the fourth leading cause of
death worldwide [1] (GOLD). COPD is characterized by in-
creasing respiratory symptoms, frequent exacerbations and
disability in activities of daily living. International and
national guidelines emphasize that COPD rehabilitation is a
key cornerstone in the standard treatment of COPD
together with smoking cessation and pharmacological
treatment [2–6]. The core elements of COPD re-
habilitation is physical exercise training, patient-
directed education and smoking cessation support,
which are recommended as mandatory in standard
COPD rehabilitation programs [2–6]. It is evident
that COPD rehabilitation result in moderate to large
clinically relevant improvements in quality of life,
symptoms, anxiety and depression, walking distance,
exercise tolerance and physical function in patients
with mild as well as very severe stable COPD and in
patients with acute phases of exacerbation [2–7].
However, approximately 50% of the patients with
severe and very severe COPD decline to participate in
COPD rehabilitation programs and 30–50% drop out
before completion of the program [8–12]. The main
reasons are severe symptoms and exacerbations,
transportation distance and lack of energy [8–12].
There are no well-established rehabilitation alternatives for
these patients, but supervised COPD tele-rehabilitation in
groups delivered by health professionals in the patients’ own
home via a computer, tablet or television screen could be a
useful approach in terms of increasing compliance and ad-
herence. Most studies on tele-rehabilitation in COPD have
been non-randomized descriptive feasibility studies and they
have reported promising effects on symptoms, physical func-
tion and quality of life [13–18]. Recently, results from three
randomized controlled trials on tele-rehabilitation have been
published [19–21]. In one study by Chaplin et al. (n= 103)
[20] per protocol analyses showed equal results in regard to
shuttle walk performance and COPD related symptoms
when comparing effects of a short term (6–8 weeks) un-
supervised web-based individually tailored home exercise
program with a 7 week conventional pulmonary rehabilita-
tion program comprising exercise and education. However,
the dropout rate was higher in the web-based program (57%
vs 23%). Another study by Vasilopoulou et al. (n= 150)21
showed that compared to a control group (usual care) the
risk of acute COPD exacerbation and hospitalization was
similar following a 12 months unsupervised individually tai-
lored maintenance tele-rehabilitation exercise program com-
bined with a weekly multidisciplinary telephone counseling
and a 12 months supervised pulmonary maintenance
rehabilitation program twice weekly at the hospital. However,
compared to the other groups the tele-rehabilitation group
had a reduced risk for visits to the emergency department.
Finally, a small study by Tsai et al. (n= 37) [19] compared
results from a non-exercising control group with results
from a supervised 8-week tele-rehabilitation program in
groups of 2–4 patients who could see and talk to both the
physiotherapist and the other participants. The study showed
significantly greater improvements in the endurance shuttle
walk time (but not in the incremental shuttle walk time or
the 6MWT), symptoms of anxiety and depression, and self-
efficacy following the supervised tele-rehabilitation program.
Thus, the new results are promising, additional effects
from face-to-face supervised COPD tele-rehabilitation in
groups compared to outpatient supervised COPD rehabilita-
tion in groups’ remains unanswered, i.e. potential higher
compliance and effects when supervised and potentially bet-
ter resource utilization when delivered in groups. To our
knowledge this study protocol currently describes the first
RCT study planned to investigate effects from equally face-
to-face supervised and group based COPD rehabilitation in
outpatient and tele-rehabilitation setting [22].
The purpose of our RCT study is to investigate the po-
tential benefits of a 10-week supervised online COPD
rehabilitation program (CORe) with conventional super-
vised COPD rehabilitation (CCRe) on walking distance
(primary outcome), muscle endurance, physical activity
level, quality of life, and COPD symptoms after comple-
tion of the intervention and at follow-up 3, 6 and
12 month later in patients with severe and very severe
(stage III-IV) COPD. This paper describes the rationale
and design of the study.
Methods
Study principles
The protocol follows the SPIRIT 2013 (Standard Protocol
Items: Recommendations for interventional Trials) and the
Template for Interventions Description and Replication
(TIDieR) checklist for description of the interventions [23,
24]. Once completed the reporting will follow the
CONSORT (Consolidated Standards of Reporting Trials)
Statement for non-pharmacologic trials [25] (Fig. 1).
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Study design
This study is a randomized controlled, assessor- and statis-
tician blinded, superiority, multicentre trial with two
parallel-groups. The trial investigates the effect of super-
vised COPD Online rehabilitation in groups, delivered by
health professionals in the patients’ own home via a com-
puter, in patients with severe and very severe (stage III-IV)
COPD (ClinicalTrial.gov-identifier: NCT02667171). Pa-
tients from the University hospitals in the Capital Region of
Denmark will be randomized to the supervised group-
based online COPD rehabilitation (CORe) or to the con-
ventional supervised COPD rehabilitation program (CCRe).
The primary outcome will be the 6-min walking distance
after completion of the COPD rehabilitation program
(primary end point at 10/12 weeks). In addition, the study
collects follow-up data at 3, 6 and 12 months after comple-
tion of the program which will be published in a separate
paper (Fig. 1 and Table 1).
The primary hypothesis is that CORe is superior to
CCRe due to a higher compliance and adherence to the
Fig. 1 Consolidate standards of reporting trials (CONSORT) flow diagram of trial design
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CORe program. We expect a mean between-group dif-
ference of 26 m in the 6-min walk test after completion
of the COPD rehabilitation programs (primary endpoint
at 12-weeks).
We also expect clinically relevant improvements in
both groups as a results of completing the COPD re-
habilitation (Table 1).
Study setting and study population
The trial is conducted at the Respiratory and Physiotherapy
Departments of eight hospitals in the capital region of
Denmark. The participating hospitals are Amager, Hvidovre,
Bispebjerg, Frederiksberg, Herlev, Gentofte, Frederikssund
and Hillerød University Hospitals, University of Copenhagen.
Recruitment of patients with severe and very severe COPD
and collection of data started March the 18th, 2016 and is
scheduled to continue until December 31st 2017 (clinical-
trial.gov registration on January 12th, 2016). The participat-
ing hospitals will provide monthly reports on patients who
accept or decline to participate and reasons for this. The
recruitment will be facilitated by a steering committee with
members from the departments of the participating
Table 1 Study measures and outcomes to be collected
Variable Baseline 10/12 weeks (post) 3-month follow-up
(22-weeks)
6-month follow-up
(36-weeks)
12-month follow-up
(62-weeks)
Primary outcomes
6 min walk distance (6MWD) X X X X
Secondary outcomes
30s sit-to-stand test (30STS) X X X X
Clinical COPD Questionnaire (CCQ) X X X X
COPD Assessment Test (CAT) X X X X
Hospital Anxiety Depression Scale X X X X
EuroQol 5D (3-L) X X X X
Other variables and outcomes
Attendance in rehabilitation X
Number of COPD related hospital admissions X X X X X
Number of COPD hospital days X X X X X
COPD related outpatient visits X X X X X
Number of COPD exacerbations X X X X X
Mortality X X X X X
Exploratory outcome
24 h–mobility (ActivePAL3tm; 5 days) X X X X
Descriptive variables
Lung function X X
FVC X X
FEV1 X X
FEV1/FVC% X X
FEV1% expected X X
Charlson morbity Index X X
Anthropometric measures
Gender X
Age X
Weight X X X X
Height X X X X
Body Mass Index (BMI) X X X X
Self-reported measures
Smoking status X X X X
Pharmacologic treatment X X X X
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hospitals. The investigator (HH) provides quarterly updates
on the recruitment progress and participates in meetings
with the clinical staff when requested.
Eligibility criteria
Potentially eligible patients will be identified and recruited
by respiratory nurses during out-patient COPD control
visits. The nurses determine eligibility according to the in-
clusion and exclusion criteria listed below:
Inclusion criteria
1. Age 18 years or older
2. Clinical diagnosis of COPD defined as the ratio of
forced expiratory volume at 1 s (FEV1) to forced
vital capacity (FVC) < 0.70 and no history of asthma
3. FEV1 < 50%, corresponding to severe or very severe
airflow limitation
4. Symptoms equivalent to the Medical Research
Council dyspnea scale (MRC) from 2 to 5
Exclusion criteria
1. Participation in/or recent completion of pulmonary
rehabilitation within the last 6 months before start
of intervention
2. Dementia/ Cognitive impairment or symptomatic
psychiatric illness
3. An impaired hearing and / or vision disability which
means that the instructions are not understood
4. Unable to understand and speak Danish
5. Unable to read Danish
6. Severe co-morbidity which means that exercise is
contraindicated
Eligible patients receive written information of the
study by the respiratory nurses and verbal information
about the study is given by the investigator or project
staff. The investigator ensures that all questions regard-
ing participation are answered before the patient is asked
to participate in the study. According to the ethical
guidelines for medical research in Denmark, all patients
are encouraged to consider consent for at least 24-h
before making the decision. Patients who agree to
participate will be asked to sign an informed consent
form to be included in the study. The patient will keep
the original document and a copy will be archived with
the Case Report Form (CRF).
Randomization
Following baseline assessments patients will be ran-
domly allocated to the intervention group (CORe) or the
comparison group (CCRe). Randomization will follow a
computer-generated block randomization list, block size
2, made by a biostatistician (TK). The randomization
will be a 1:1 randomization block from each recruiting
hospitals.
Blinding
To ensure concealment of allocation a senior manager
from another research department with no interest in
the project, will provide the draw and will be responsible
for the randomization list, which will not be available to
the investigator. The senior manager will inform the
investigator about the allocation, and the investigator or
the project staff will subsequently inform the patient
about the allocation and when to begin CORe or CCRe.
All assessors are blinded to group allocation and previ-
ous test results. Due to the nature of the study the
patients cannot be blinded, but prior to the assessments
they are reminded not to disclose their group allocation
to the assessors. In case of failure keeping the outcome
assessor blinded (that is, if a participant reveals his/her
allocation) a second assessor will be available to step in
and conduct the assessment on another day.
To avoid experimenter’s (subconscious) bias the bio-
statistician who perform the data analyses and validate
the results will be blinded to group allocation. The
research group will interpret the results, and the conclusion
will be prepared in two versions before the allocation code
is broken (one assuming that arm A is the intervention,
and one assuming that arm B is the intervention).
Sample size
For the study’s primary endpoint, the 6-min walk test
(6MWT) which assesses distance (in meters, 6MWD)
walked over 6 min, a change of 26 m is considered to be
a minimal clinically relevant difference (MIREDIF) in pa-
tients with severe and very severe COPD [26, 27]. Based
on a two-sample independent t-test with the given MIR-
EDIF of 26 m, standard deviation of 44.6 m based on
data published by Puhan et al. 2011 [27], power of 80%
and significance level of 0.05 47 patients will be needed
in each group, 94 in total. A dropout rate of 30% is as-
sumed, resulting in 134 patients being included in the
final study population.
Power estimations for secondary outcomes
We performed power estimations for all secondary out-
comes based on the decided inclusion of 134 (67 in each
group) patients, and expected standard deviation (SD) and
an existing minimal clinical important difference (MCID)
for each outcome (Table 2). The decided sample size
makes it possible to detect clinically relevant differences in
secondary outcomes for respectively; muscle strength and
leg endurance, symptoms, anxiety and depression, and
health-related quality of life (HRQOL) all corresponding
with a power above 80% to reject the null hypothesis (type
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I error 5%). The outcomes for disease specific quality of
life and physical activity were both have a power below
80%, and must be considered as exploratory outcomes
(Table 2).
Study groups
Warm-up in both groups (CCRe and CORe)
Warm-up has duration of 5 min (in CORe group) and
10 min (in CCRe group). The aim is familiarization of
movements, increasing range of motion and stimulation
of joints, muscles and cardiorespiratory warm-up in ac-
cordance with recommendations from the American
College of Sports Medicine [28]. The warm-up protocol
is presented in Table 3.
Comparison group - conventional COPD rehabilitation
programme (CCRe)
Patients in the comparison group will receive the super-
vised standard COPD Rehabilitation program (CCRe) for
patients with severe and very severe (stage III-IV) COPD,
which follows the Danish Health Authority’s National
Clinical Guideline and the Regional Guidelines [6, 29, 30].
The guidelines allow for minor variations in the duration
of the program (from 10 to12 weeks) but not in the con-
tent of the program [6, 29, 30]. The rehabilitation program
contains exercise and patient education. Exercise sessions
last 60 min twice weekly and will be supervised by skilled
physiotherapists with at least 2 years of experience with
COPD rehabilitation. The content of the physical exercises
is presented in Table 4. Patient education sessions of 60–
90 min will take place once weekly following the exercise
session. The total number of patient education sessions
will vary from 10 to 12 lessons (including follow-up ses-
sions). Topics covered in the education program are pre-
sented in Table 5.
Intervention group - COPD online rehabilitation programme
(CORe)
Patients in the intervention group will receive the super-
vised COPD Online Rehabilitation Program (CORe),
which is an intervention that has never been systematic-
ally offered in Denmark. The CORe intervention is su-
pervised by skilled physiotherapists and respiratory
nurses with at least 2 years of experience with COPD re-
habilitation, and delivered via a web-cam at Bispebjerg
Hospital to a group of 4–8 patients who exercise at
home and communicate via a computer. Each session is
60 min, i.e. 35 min of exercise and 25 min of patient
education, three times per week for the duration of
10 weeks. The exercises used in CORe exercise program
were identified and selected amongst exercises used in
previous exercise intervention studies on patients with
severe or very COPD and involves larger muscle groups
with 50/50% exercises for upper and lower extremities,
respectively [4, 5, 31–36]. Volume, intensity and content
specified in the training protocol is in accordance with
both national and international exercise recommenda-
tions [4–6, 29, 30, 37, 38]. The exercises (Tables 6 and
7) are executed in four sets to achieve peripheral muscle
fatigue and secondary dyspnea/breathlessness. Each set
is carried out in a predefined period of 20 to 40 s with a
maximum number of repetitions performed, i.e. 8 to 25
repetitions depending on the patients exercise capacity
and motivation [28, 39], but with the aim of 12 to 20
repetitions. The pause is predefined from 40 to 20 s
(Table 6). The exercise velocity is based on recommen-
dations applying to high-repetitive exercises (> 15 repeti-
tions) [28], i.e. moderate to high speed equaling 1–2 s
for both the concentric and the eccentric movements.
The exercise load is body weight supplemented by exter-
nal weight using dumbbells (1 to 10 kg). The intensity is
estimated to be equivalent to 40–80% of one repetition
maximum (8–25 repetitions), and exercises are per-
formed as high repetitive time-based muscle endurance
training at least 80% of the exercise time corresponding
to a weekly volume of 90 min (30 min × 3 sessions). In
practice the training intensity is determined by using the
self-rated Borg CR-10 scale (score range 0–10), and the
aim is to achieve a training intensity corresponding to
score 4–7 (moderate to very strong shortness of breath
during the exercises).
The first 2 weeks serve as a familiarization phase with
the purpose to adapt to exercising, adjusting and opti-
mizing load and to avoid musculoskeletal overload injur-
ies. Thus, exercises for the lower extremities (Table 6:
exercise # 1, 3, 5) are carried out without dumbbells at
the first session. If a patient can perform three consecu-
tive sets without resting during the active period exter-
nal load is added at the following training session. The
external load increase ranges from 2 to 4 k (total weight
Table 3 Warm-up protocol – intervention COPD online
rehabilitation
Time Exercises Intensity Progression
Warm-up
(duration
5 min)
Sitting or standing:
-Heel uprisings (uni- or
bilateral),
- Kneeextension
- rear deltoid row
- chest press
movement
- Vertical shoulder
press’
(uni- or bilateral).
Standing:
-Walking on site
- side to side walking
- leg curl
- leg swing
- squats
Non-specific intensity
Purpose:
-increase body
temperature
- cardiorespiratory
warm-up
-muscle and tendon
tissue warm-up
none
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for two dumbbells) when progression adjustments are
made. Exercises for the upper extremities (Table 6: exer-
cise # 2, 4, 6) are carried out with the smallest weights
(1 kg / pcs.) at the first exercise session. If a patient can
perform three consecutive sets without resting during
the active period external load is added at the following
training session. The external load increase ranges from
2 to 4 k (total weight for two dumbbells) when progres-
sion adjustments are made. Progressions are assessed in-
dividually from session to session [31–34]. In addition
the patients are asked to count their repetitions in each
set every 6th sessions, and if the number of repetitions
exceeds 25 the external load is increased at the next
training session.
Exercise log
Each patient has an exercise log, which is completed by
the supervisor who instructs the sessions online. The ex-
ercise log contains the number of completed sets, loads
in kilo, customized additions and non-completed sets for
each of the participants for all sessions.
Table 4 Exercise content comparison group - conventional COPD rehabilitation
Exercise type Exercises Intensity Progression
Warm-up
(duration 5-10 min)
Sitting or standing:
-Heel uprisings (uni- or
bilateral),
- Kneeextension
- rear deltoid row
- chest press movement
- Vertical shoulder press’
(uni- or bilateral).
Standing:
-Walking various
- leg curl
- leg swing
- squats
Non-specific intensity
Purpose:
-increase body temperature
- cardiorespiratory warm-up
-muscle and tendon tissue Warm-up
none
Endurance training
(duration 20-30 min)
-Walking or
-Cycle or
- Treadmill or
- Circuit training or
- Activity games
Borg CR-10 dyspnea 4–7
Exercises performed in intervals or
continuous
Every 2nd to 4th week
load adjustment individualized
Resistance training
Duration 20-30 min)
Machine:
-leg press
-knee extension
Pull down and/or chestpres
(vertical)
Other equipment for strength
circuit training
elastic band
Dumbbells
Weight cuff
40–80% of 1RM corresponding from
8 to 25 repetitions
2-3sets
Every 2nd to 4th week load
adjustment individualized
(repetition counting by
supervisor)
Cool-down
(duration5-10 min)
Breathing exercises
Pursed lip breathe
Relaxation exercises
Yoga exercises
Non-specific intensity Non-specific
Responsible health profession: Physiotherapist
Monitoring of intensity may vary, but it is expected that hospitals use either objective (pulse or Watt monitoring) or subjective (CR Borg scale for dyspnea)
measurements for intensity monitoring
Resistance training will be evaluated for progression by counting their maximal repetition and estimate a new optional weight/resistance within 8–25 repetitions
Workout logs from every training session are recommended registered by the authorization law
Table 5 Patients educations topics control group –
conventional COPD rehabilitation
Topics/themes Communication/ learning form
• COPD and the treatment
• The importance of
smoking cessation
• The importance of daily
activity and exercise
• The importance of
nutrition
• Medication and use of
devices and inhalation
technics
• Early signs of exacerbation
and action plan
• Use of nebulizer apparatus
and oxygen apparatus.
Individually smoking
cessation and dietician will
be optional for the
individual COPD patient if
assessed relevant.
Topics are promoted as a combination of:
• Information
• Dialogue
• Reflection exercises
• Practical exercises
• Focusing on increasing the
individual’s self-competence
• Networking and exchange
of experience.
Responsible health profession: Respiratory nurse
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Patient education
The education topics are disseminated as a combination
of dialogue, reflection exercises and practical exercises
[30, 40] (Table 8). Overall the topics are similar to those
in CCRe group (Table 5), but delivered as 20 min ses-
sions three times per week in total 30 sessions. The
medical and nutrition topics are provided by a respira-
tory nurse. The dissemination focus is in particular on:
 Participation and dialogue to facilitate sustainable
knowledge related to COPD
 Creating space for reflection and deliver opportunity
for the patient’s own action plan for handling the
disease
 Awareness and acceptance of patients’ different ways
in understanding and acquire knowledge
 Promoting the positive aspects and opportunities in
life with COPD
Statistical analysis
Descriptive data
Descriptive data for the intervention and comparison
groups will be compared using Chi-square test or Fishers
exact test for categorical variables, the Student’s t-test for
normally distributed continuous variables, if the normality
can’t be assumed non-parametric Mann-Whitney U test
will be used instead. Descriptive variables will be pre-
sented as means, standard deviation, medians with range
or frequencies with percentages depending on the distri-
bution of the variable.
Analysis of primary and secondary outcome
Difference between intervention groups in primary
and secondary outcomes at 10/12 week follow-up are
analyzed by mixed effect models. Models will include
treatment, age, gender, BMI, FEV1 and smoking
status, and random effect assessor, hospital allocation
and subject. Normal distribution of the model resid-
uals is evaluated by QQ-plots, transformation of out-
come may be used if distribution of residuals are not
normal. All models will be fitted as listed above, in
the event that convergence is not possible or other
fitting issue the model structure will be reduced and
reasoning for changes will be mentioned.
If all missing data is missing at random, maximum
likelihood estimation in the mixed effect models can be
done under assumptions of ignorability to account for
missing data.
Secondary outcomes will also be analyzed mixed effect
model with the same fixed and random effects as the
primary outcome.
No interim analysis will be made. Statistical analyses
will be carried out using R 3.2.2 (R Foundation for
Statistical Computing, Vienna, Austria). P-values of less
than 0.05 are considered statistically significant.
Table 6 Exercise protocol intervention group COPD online rehabilitation (Chronological order)
Exercise# Exercise name Extremities Uni/bilateral execution Bodyposition Time/volume Exercise load
1 Sit-to-stand Lower extremities Bilateral Sitting and standing Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Bodyweight and
dumbbells
2 Biceps curl -shoulder
press
Upper extremities Bilateral Standing Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Dumbbells
3 Step-up Lower extremities Bilateral Standing Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Bodyweight,
dumbbells and
stepbox
4 Bent Over Rowing Upper extremities Unilateral Standing
Upper body slightly
forward bended
Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Dumbbells
5 Static-dynamic Squat Lower extremities Bilateral Standing Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Bodyweight and
dumbbells
6 Front Raise Dumbbells Upper extremities Bilateral Standing Active: 80-160 s.
Rest:160-80s.
Total: 240 s.
Dumbbells
Table 7 Progression model - intervention group COPD online rehabilitation (Chronological order)
Phase Week number Working volume in seconds Rest volume in seconds Number of sets for each exercise
Familiarization 1–2 20 40 4
Progression 1 3–6 30 30 4
Progression 2 7–10 40 20 4
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Health economic analysis
Costs related to the interventions are calculated based
on the expenses associated with exercise instruction and
support, the time spent by participants and relatives,
transportation costs and the participants’ use of health
care services. Cost-effectiveness (cost per quality-
adjusted life year) is estimated from these cost calcula-
tions combined with changes in EQ-5D-5 L scores over
time during the observation period. Costs related to
COPD treatment and involved in the use of health care
services by patients and relatives are estimated from na-
tional administrative health registries.
The Health economic analysis will be published in a
separate publication and a potential business case con-
ducted by an independent consultant company.
Compliance
In addition to the intention-to-treat analysis, we will also
perform a per-protocol analysis. The participants in both
groups must have completed 70% per cent of the COPD
rehabilitation program to be included in the per-
protocol analysis.
Data collection
Blinded assessors perform pre- post- and follow-up
tests and collect data in CRF’s at five locations
(Bispebjerg-, Hvidovre-, Gentofte-, Herlev- and
Frederikssund University Hospitals) to cover the
whole Capital Region. To the extent possible, the
same assessor tests a participant at all test times. For
practical reasons all locations have two to three asses-
sors available. All assessors have completed a four-
hour assessor course to ensure that they follow the
same testing protocol, and that test procedures and
recording of results are standardized. In addition, they
have observed at least four live tests before being
accredited to start as blinded assessors. All assessors
are familiar with the physical performance tests
(6MWT and 30-s Sit-To-Stand test) from clinical
practice and evaluation.
Data management
All CRF’s and paper questionnaires will be checked for errors
and missing data before being entered in log-protected
spreadsheet database. All entered data will be double-
checked against the CRF, range checked and exported to
relevant statistical software (SPSS, R, GraphPad). The
principal investigator will have access to the full dataset, and
co-investigators and steering committee will have access as
needed for random auditing. All paper-based CRF’s and
questionnaire versions will be anonymized and locked in a
filing cabinet to ensure confidentiality. Data management
will comply with the rules of the Danish Data Protection
Agency.
Outcomes
Primary outcome measure
The 6-min walk test (6MWT) will be used to assess en-
durance and walking capacity. The 6MWT is widely
used for measurement of endurance walking capacity in
patients with COPD [4, 41]. The test is performed in ac-
cordance with standardized guidelines [41]: the walking
course is 20 m due to walking space shortage at some
locations and to ensure same standard walking length at
all five locations [42]. The patients will be instructed to
walk as far as possible in 6 min; receive recommended
standardized encouragement; two tests are performed to
eliminate a potential learning effect and the highest
value is recorded; a 30-min rest is mandatory between
the first and second 6MWT.
Secondary outcome measures
The 30-s sit-to-stand test (30s-STS) will be used as an in-
direct assessment of lower extremity muscle strength
[43, 44]. A standardized chair with a seat height of 45–
47 cm is used, and the patients will be asked to stand up
Table 8 Patients educations protocol – intervention group COPD online rehabilitation
Topic/themes Communication/ learning form Week Duration Number of sessions
Welcome and individual presentations Information, dialogue 1 20 min 3
COPD and the treatment Information, dialogue 2 20 min 3
Early signs of exacerbation and action plan Information, dialogue, reflection 3 20 min 3
Medication and use of devices and inhalation technics
Use of nebulizer apparatus and oxygen apparatus.
Information, dialogue, reflection, practical exercises 4 20 min 3
Physical activity and exercise Information, dialogue, reflection 5 20 min 3
Food, importance of food in COPD Information, dialogue, reflection, practical exercises 6 20 min 3
Smoking, cessation, substitution Information, dialogue, reflection 7 20 min 3
Anxiety management, relaxation Information, dialogue, reflection 8 20 min 3
Repetition 9 20 min 3
Group needs 10 20 min 3
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fully and sit down as many times as possible in 30 s with
the arms across the chest. The numbers of full stands
will be recorded. The score zero will be recorded if a
patient is unable to rise from the chair without using the
arms. Two tests will be performed to eliminate a
potential learning effect, and the best result will be
recorded. A 30-min rest is mandatory between first and
second 30s-STS.
COPD Assessment Test (CAT) is a patient completed
8-item questionnaire that assesses the impact of COPD
on self-reported health status and symptoms [45]. Each
item scores from 0 to 5 points (0 indicating no impact
or symptoms, 5 worst possible impact or symptoms)
summing up to a total CAT score range of 0–40 points.
CAT is a validated tool with a Cronbach’s α of 0.88 and
found responsive to change in self-reported health status
and symptoms after pulmonary rehabilitation [45–47]. A
minimal clinical important difference (MCID) of 2–3
points is suggested [47, 48].
Clinical COPD Questionnaire (CCQ) measures self-
reported quality of life [49]. CCQ consist of 10-itmes
with an overall score and 3-domain scores: Symptoms
(4-Items), Functional state (4-Items) and Mental state
(2-Items) [49]. Overall- and domain scores ranges from
0 to 6 (0 = no impairment). The CCQ is a validated tool
with a Cronbach’s α of 0.91 for the total score and 0.78,
0.89, 0.80 respectively for the symptoms, functional and
mental scores and has a interclass correlation coefficient
of 0.94 [49]. A MCID of 0.4 point is suggested [50, 51].
Hospital Anxiety and Depressions Scale (HADS) is a
14-item questionnaire that assesses anxiety and depres-
sion level in medically ill persons [52]. The scale offers
two sub scores HADS anxiety (HADS-A) and HADS de-
pression (HADS-D), and consists of seven questions to
assess anxiety and seven questions to assess depression.
Each question scores from 0 to 3 (0 = no symptoms).
HADS is a validated tool with Cronbach’s α of 0.83
(HADS-A) and 0.82 (HADS-D) [52]. Scores of 0–7 from
each of the two subs scales are considered normal and
scores of 8–10 suggest a risk of anxiety and/or depres-
sion disorder. Scores of 11 and above suggest the prob-
able presence of anxiety and/or depression disorder [52].
A MCID of 1.5 point in each scale is suggested based on
both anchor and distribution-based methods [53].
EuroQol 5-Dimension Questionnaire (EQ-5D), is gen-
eric self-reported global measure for health-related qual-
ity of life [54]. EQ-5D compromises a 5-dimension
(mobility, self-care, usual activities, pain/discomfort, and
anxiety/depression) questionnaire and a 20 cm visual
analog scale (EQ-VAS) ranging from zero (worst imagin-
able health) to 100 (best imaginable health) [54]. A
MCID of 8-points in EQ-VAS is suggested in persons
with COPD, while no MCID is established in the
5-dimension questionnaire in persons with COPD [55].
24-h physical activity is measured with an activePAL ™
triaxial accelerometer (PAL Technologies Ltd., Glascow,
UK). The patients will be asked to wear an activePAL™
on the thigh 24 h per day for 5 days prior to randomization;
5 days during the intervention period (after 5–7 weeks); 5
days after completion of intervention period; 5 days
3 months after intervention completion; and 5 days
12 months after completion of the intervention. The 24-h
physical activity level is an exploratory outcome in this
study. Due to limited staff resources and geographical
transportation issues activity level will only be measured in
the first 68 patients (approximately 50% of the population)
who live within a radius of 25 km from Bispebjerg Univer-
sity hospital. The activePAL™ accelerometer is attached on
the front of the thigh and measures time spent lying/sitting
(thigh in horizontal position), and time spent standing and
walking (thigh in a vertical position), the number of steps
taken, cadence, and the number of sit-to-stand and
stand-to-sit transitions. The activePAL™ is a valid and reli-
able measure of posture and transitions in mobility limited
older adults and adults with severe and very severe COPD
[56–58]. A MCID of 600–1100 steps per day is suggested
in persons with COPD, depending on which distribu-
tion based method you rely on [59]. However active-
PAL™ underestimates step rate at slow walking speeds
compared to observed step counts, while use of walk-
ing aid such as rollator and crutches do not differ
from observed step rate counts [58]. Walking speed
between 2.4–5.6 km/h is preferable to get valid data
on time spent walking [56, 60] and consequently
walking could potentially be categorized as standing
in those walking slower 2.4 km/h [56, 60]. For this
reason we will dichotomize data into time spent sed-
entary (lying/sitting) and upright (standing/walking).
Reliability calculations
Intra- and inter tester reliability will be calculated on
physical outcome measures (6MWT and 30s-STS) in
fifty consecutively recruited patients. The retest is
completed seven to 10 days after baseline assessment
and prior to intervention start. The reliability in the
patient reported questionnaires (CAT, CCQ, HADS,
EQ-5D) will be calculated in the same sample of fifty
patients.
The reliability for the physical outcome measures and
patient reported outcomes will be published in separate
articles.
Other variable and outcomes
Other variables and outcomes will be registered as
mandatory in the hospital registry system and used as
descriptive as well as explanatory variables for the pri-
mary and secondary outcomes (Table 1).
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Demographic, descriptive variables
Age, gender, height, weight, body mass index, marital status,
education, smoking status, years with COPD, Charlson mor-
bidity index and lung medications are registered at baseline
assessment.
The lung spirometry is conducted at the respiratory
department of the referral hospital by a lung physician
or respiratory nurse before baseline and 12-month
follow-up assessments. All hospitals use clinically
approved spirometry equipment while manufacture
trademark varies between hospitals in the Capital Region
(Table 1).
Publication process
HH are obligated to ensure that the results of the study
are published in due time after completion of the study.
Changes to initial plan
In the initial registration of the study, we planned to do
the outcome measure pre-, post- and 3 month follow-up
on the performance- and self- reported outcome mea-
sures (Fig. 1 and Table 1), while 6-month, 12-month
follow-up should be based on register data defined as
number of hospital admission related to COPD, number
of hospitals admission days related to COPD, number of
outpatient visits related to COPD and mortality. After
reconsideration, the steering committee decided to
prepare an additional protocol and apply the ethical com-
mittee for permission to perform 12 months of follow up
on performance- and self- reported outcome measures.
All patients already included will be asked retrospectively
to enter and participate in a 12 month follow up test. Pro-
spectively participation in the 12 months of follow up is
not mandatory to be included in the CORe trial. A new in-
formed consent form is filled if the participant accepts
“extra” participation in the 12 months of follow up.
Adverse event reporting
Adverse events are recorded in the CRF. The protocol
distinguishes between adverse events that may be dir-
ectly attributable to the study interventions and the
monitoring of adverse events not attributable to the
study. Serious adverse events are reported within 24 h to
the principal investigator. The steering committee con-
sisting of a pulmonologist, respiratory nurse and clinical
physiotherapist surveys the study and evaluates serious
adverse events.
Discussion
To our knowledge there are currently no RCT studies
published comparing supervised outpatient COPD
rehabilitation in groups with supervised COPD tele-
rehabilitation in groups [13–21]. McCarthy et al. 2015
confirmed that COPD rehabilitation indeed is beneficial
in clinical trials [2]. However in the real world COPD re-
habilitation, we know that compliance amongst the pa-
tients with COPD is low and potentially insufficient due
to frequent exacerbation, hospitalization, transportation
dependency, uniform offered outpatient COPD rehabili-
tation in hospitals, municipalities and other outpatient
settings. This study provides a detailed description of a
simple, fully supervised COPD Online rehabilitation pro-
gram, which aims to provide high frequent attendance
with a minimal time consuming exercise and educational
approach. The choice of exercises, equipment, frequency
and duration was chosen in order to investigate whether
a few specific but simple exercises, can improve endur-
ance, strength, physical activity, symptoms related to
COPD and HRQOL.
This approach was chosen to facilitate implementation
of a minimally equipped home based online supervised
COPD rehabilitation program, which might be more
feasible and thereby more efficient than conventional
COPD rehabilitation in patients with severe and very se-
vere COPD. A problem in previous exercise studies is
the lack of standardization which makes reproducibility
difficult. The comprehensive standardization of exercise
and progression protocol in this trial facilitates the re-
producibility of this trial.
The results from this study will most likely provide im-
portant knowledge regarding treatment of Patients with
COPD who are unable or non-compliant to conventional
offered COPD rehabilitation settings. The study will also
contribute to the existing knowledge regarding reasons for
accepting and declining participation in CCRe and CORe,
characteristics of completers and non-completers, and the
long term effects of the two rehabilitation approaches.
The CORe-Trial is designed from high quality criteria in a
non-pharmacological clinical trial, with a multicenter de-
sign which reduces risk of selection bias. Assessors and
biostatistician are blinded to intervention, which should
reduce detection and interpretation bias. The research
group will be blinded when interpreting data and writing
the conclusion.
Trajectory
Inclusion was initiated 18th of March 2016 and will con-
tinue until 31st of December 2017.
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